← All trials
NCT05509153
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2022
- Primary completion
- Nov 1, 2026
- Completion date
- May 1, 2027
- First posted
- Aug 19, 2022
- Last posted
- Aug 24, 2022
- Enrollment
- 160
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Western Sydney Local Health DistrictLead sponsor
- Western Sydney Local Health DistrictOverall official - principal investigator
- Western Sydney Local Health DistrictReponsible party - principal investigator
- Deakin UniversityCollaborator
- Melbourne HealthOverall official - principal investigator
- Monash UniversityCollaborator
- University of MelbourneCollaborator
- University of SydneyCollaborator
- University of QueenslandCollaborator
- University of QueenslandOverall official - principal investigator
- University of Western AustraliaCollaborator
- Calvary Health Care BethlehemOverall official - principal investigator
- The Perron InstituteOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.